ClinicalTrials.gg
RecruitingNCT05127005FINTASYUpdated Nov 2, 2026

Efficacy of Trapeziectomy Versus Sham Surgery in the Treatment of Osteoarthritis at the Base of the Thumb

An interventional study of Trapeziectomy and Sham in Thumb Osteoarthritis, sponsored by Tampere University Hospital. Recruiting at 4 sites in Finland. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Tampere University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Osteoarthritis with a site in Finland — 5 open to participants now, 10 under way, none of them phase 3. Osteoarthritis · Finland.

Planned enrollment
12th of 25
132 · median 120
Started
2022
the only one that year
No phase
15 of 37
3 open now
Registered
34th of 37
by date
Lead sponsor
2 of 37
Tampere University Hospital

Among the 37 studies in Osteoarthritis with a site in Finland, this one is the 12th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2022, is one of 15 with no phase, and was the 34th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

5 of the 37 studies in Osteoarthritis with a site in Finland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Osteoarthritis with a site in Finland, or all of them as a file.
02

Study summary

A multi-center randomized placebo-controlled clinical trial which determines the efficacy of trapeziectomy in patients with persistent painful osteoarthritis at the base of the thumb. The primary outcome is patient reported evaluation of pain and function of the wrist and hand at 6 months after the randomization to treatment group.

Read the detailed description

A multi-center randomized placebo-controlled clinical trial which determines the efficacy of trapeziectomy in patients with persistent painful osteoarthritis at the base of the thumb (CMC1). The primary outcome is Patient Rated Wrist and Hand Evaluation (PRWHE) at 6 months after the randomization to treatment group. Secondary measures include PRWHE at 3 months, 1 year, 2 years and 5 years, grip strength, and global assessment of change.

03

Conditions studied

  • Thumb Osteoarthritis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Primary thumb basal joint (CMC1) osteoarthritis (Eaton Glickel grade 2 or higher) confirmed by standard x-rays and with symptoms limiting activities of daily living
  2. Indication for surgical treatment of thumb basal joint (CMC1) osteoarthritis after insufficient benefit from non-operative treatment, including use of a thumb orthosis and pain medication (NSAIDs or paracetamol, implemented for at least three months.
  3. Thumb pain in use of at least 4 on a 0 to10 numerical rating scale (NRS, 10=worst pain)
  4. Age > 45 years
  5. ASA-classification I-II (American Society for Anesthesiologist's Physical Status Classification System)
  6. Ability to speak, understand and read in the language of the clinical site
  7. Provision of from the participant
  8. Shared decision to proceed with surgical treatment of CMC-1 OA

Exclusion criteria

Exclusion Criteria:

  1. Patients' main complaint is due to some other problem than primary thumb basal joint (CMC1) osteoarthritis or patient will undergo any other surgery in conjunction with trapeziectomy
  2. Neurologic condition affecting the function or symptoms of the upper extremity
  3. \<6 months from other surgical procedure of the upper extremities
  4. Rheumatoid arthritis or other inflammatory joint disease
  5. Bilateral thumb basal joint (CMC1) osteoarthritis in which patient requests treatment for both sides
  6. Previous operation due tothumb basal joint (CMC1) osteoarthritis for either side
  7. >45 degrees of hyperextension in the thumb MP joint in resting position (zig zag deformity)
  8. Patient is unable to continue his/her current job due to thumb pain
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Trapeziectomy

    Trapeziectomy

    Procedure: Trapeziectomy

  • Placebo comparator
    Placebo surgery

    Placebo surgery

    Procedure: Sham

  • Other
    Non-randomized observational arm

    Non-randomized observational arm (trapeziectomy, not blinded)

    Procedure: Trapeziectomy

Interventions

  • ProcedureTrapeziectomy

    Surgical excision of trapezium bone

  • ProcedureSham

    Skin incision only

06

What researchers measure

Primary outcomes

  1. Patient rated wrist and hand evaluation (PRWHE)

    PROM questionnaire: PRWHE is a valid wrist and hand-specific composite measure comprising pain and function.

    Time frame: 6 months after randomization

Secondary outcomes

  1. Patient rated wrist and hand evaluation (PRWHE)

    PROM questionnaire: PRWHE is a valid wrist and hand-specific composite measure comprising pain and function.

    Time frame: At baseline, 3 months, and 1, 2, 5 years after randomization, 6 months after possible secondary trapeziectomy

  2. Global improvement (PGI-C)

    PROM, question (Likert scale)

    Time frame: At 3 and 6 months, and 1, 2, and 5 years after randomization, 6 months after possible secondary trapeziectomy

  3. Patient Acceptable Symptom State (PASS)

    PROM, question (Likert scale)

    Time frame: At 3 and 6 months, and 1, 2, and 5 years after randomization, 6 months after possible secondary trapeziectomy

  4. Patient rated wrist and hand evaluation (PRWHE) - pain subscale

    PROM questionnaire

    Time frame: At baseline, 3 months, 6 months, and 1, 2, 5 years after randomization, 6 months after possible secondary trapeziectomy

  5. Patient rated wrist and hand evaluation (PRWHE) - function subscale

    PROM questionnaire

    Time frame: At baseline, 3 months, 6 months, and 1, 2, 5 years after randomization, 6 months after possible secondary trapeziectomy

  6. EuroQol EQ-5D-5L, index value

    PROM, health-related quality of life questionnaire

    Time frame: At baseline, 3 and 6 months, and 1, 2, and 5 years after randomization

  7. EuroQol EQ-5D-5L, Visual Analogue Scale (VAS) (EQ VAS)

    PROM, health-related quality of life questionnaire

    Time frame: At baseline, 3 and 6 months, and 1, 2, and 5 years after randomization

  8. Grip strength

    Measured with dynamometer

    Time frame: At baseline, 6 months after randomization

  9. Pinch strength

    Measured with dynamometer

    Time frame: At baseline, 6 months after randomization

  10. Pain medication

    Frequency of pain medication for thumb pain in the past week (categorial, 4 step)

    Time frame: At baseline, 3 months, 6 months, and 1, 2, 5 years after randomization

  11. Harms

    Harms and healthcare contacts related to the operated hand will be collected systematically and unprompted using a standardized electronic case report files (eCRF). Events will be classified by type (Adverse event, Serious Adverse Event, Suspected Unexpected Serious Adverse Reaction), attribution, timing, and nature.

    Time frame: After intervention (intraoperative), at 3 months, 6 months, and 1, 2, 5 years after randomization and as unprompted participant contacts

Other outcomes

  1. Adherence to post operative rehabilitation

    Patient rated proportion of adherence, 0-100%

    Time frame: at 3 months after randomization

  2. Unblinding

    Number of unblinded participants per group

    Time frame: at 3 months, 6 months, and 1, 2, 5 years after randomization

  3. Cross-over

    Number of unblinded participants per group

    Time frame: at 3 months, 6 months, and 1, 2, 5 years after randomization

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — In this trial IPD sharing is restricted by data protection regulations

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Sep 2028, 80 months after the start.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 80 months is above that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Dec 2024 → Sep 2028 and completion Dec 2029 → Mar 2033.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2021
First posted
Nov 19, 2021
StartActual
Jan 20, 2022
Primary completionEst.
Sep 30, 2028was Dec 2024
CompletionEst.
Mar 31, 2033was Dec 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Finland)
  • Central Finland Hospital Nova · Jyväskylä, Finland
  • Kuopio University Central Hospital · Kuopio, Finland
Show 2 removed
  • Central Finland Central Hospital · Jyväskylä, Finland
  • Kuopio University Hospital · Kuopio, Finland
Nov 2, 2026
Primary completion
Dec 2024→Sep 30, 2028
Nov 2, 2026
Study completion
Dec 2029→Mar 31, 2033
Nov 2, 2026
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedShared decision to proceed with surgical treatment of CMC-1 OA
Nov 2, 2026
Interventions
Arm changed Sham surgery→Placebo surgery
Nov 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPatient reportedrated wrist and hand evaluation (PRWHE)Time frame: 6 months → 6 months after randomization
Nov 2, 2026
Secondary outcomes
5 edited, 9 added
What changed in the outcomes
  • EditedPatient reportedrated wrist and hand evaluation (PRWHE)Time frame: 3 months, and 1, 2, 5 years → At baseline, 3 months, and 1, 2, 5 years after randomization, 6 months after possible secondary trapeziectomy
  • EditedPatient accepted symptom stateAcceptable Symptom State (PASS)Time frame: 3 and 6 months, and 1, 2, and 5 years → At 3 and 6 months, and 1, 2, and 5 years after randomization, 6 months after possible secondary trapeziectomy
  • EditedGrip and pinch strengthTime frame: 6 months → At baseline, 6 months after randomization
  • EditedEUROQOLEuroQol EQ-5D-5L, index valueTime frame: 3 and 6 months, and 1, 2, and 5 years → At baseline, 3 and 6 months, and 1, 2, and 5 years after randomization
  • ChangedBefore Global improvementNow Global improvement (PGI-C)Time frame: 3 and 6 months, and 1, 2, and 5 years → At 3 and 6 months, and 1, 2, and 5 years after randomization, 6 months after possible secondary trapeziectomy
  • AddedPatient rated wrist and hand evaluation (PRWHE) - pain subscaleTime frame: At baseline, 3 months, 6 months, and 1, 2, 5 years after randomization, 6 months after possible secondary trapeziectomy
  • AddedPatient rated wrist and hand evaluation (PRWHE) - function subscaleTime frame: At baseline, 3 months, 6 months, and 1, 2, 5 years after randomization, 6 months after possible secondary trapeziectomy
  • AddedEuroQol EQ-5D-5L, Visual Analogue Scale (VAS) (EQ VAS)Time frame: At baseline, 3 and 6 months, and 1, 2, and 5 years after randomization
  • AddedPinch strengthTime frame: At baseline, 6 months after randomization
  • AddedPain medicationTime frame: At baseline, 3 months, 6 months, and 1, 2, 5 years after randomization
  • AddedHarmsTime frame: After intervention (intraoperative), at 3 months, 6 months, and 1, 2, 5 years after randomization and as unprompted participant contacts
  • Addedother outcomeAdherence to post operative rehabilitationTime frame: at 3 months after randomization
  • Addedother outcomeUnblindingTime frame: at 3 months, 6 months, and 1, 2, 5 years after randomization
  • Addedother outcomeCross-overTime frame: at 3 months, 6 months, and 1, 2, 5 years after randomization
Nov 2, 2026
Contact
Study contact's phone or email changed: j•••@pshp.fi→j•••@pirha.fi. See the current contact
Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Helsinki University Central Hospital · Helsinki, FinlandContact none listed→S•••@hus.fi · •••4955
Nov 2, 2026
Sponsor
Collaborators added: Hospital Nova, Central Finland·Kuopio University Hospital; collaborators removed: Central Finland Central Hospital·University of Eastern Finland
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Finland)
    • Central Finland Hospital Nova · Jyväskylä, Finland
    • Kuopio University Central Hospital · Kuopio, Finland
    Show 2 removed
    • Central Finland Central Hospital · Jyväskylä, Finland
    • Kuopio University Hospital · Kuopio, Finland
    Primary completion Dec 2024→Sep 30, 2028
    Study completion Dec 2029→Mar 31, 2033
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedShared decision to proceed with surgical treatment of CMC-1 OA
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPatient reportedrated wrist and hand evaluation (PRWHE)Time frame: 6 months → 6 months after randomization
    Secondary outcomes 5 edited, 9 added
    What changed in the outcomes
    • EditedPatient reportedrated wrist and hand evaluation (PRWHE)Time frame: 3 months, and 1, 2, 5 years → At baseline, 3 months, and 1, 2, 5 years after randomization, 6 months after possible secondary trapeziectomy
    • EditedPatient accepted symptom stateAcceptable Symptom State (PASS)Time frame: 3 and 6 months, and 1, 2, and 5 years → At 3 and 6 months, and 1, 2, and 5 years after randomization, 6 months after possible secondary trapeziectomy
    • EditedGrip and pinch strengthTime frame: 6 months → At baseline, 6 months after randomization
    • EditedEUROQOLEuroQol EQ-5D-5L, index valueTime frame: 3 and 6 months, and 1, 2, and 5 years → At baseline, 3 and 6 months, and 1, 2, and 5 years after randomization
    • ChangedBefore Global improvementNow Global improvement (PGI-C)Time frame: 3 and 6 months, and 1, 2, and 5 years → At 3 and 6 months, and 1, 2, and 5 years after randomization, 6 months after possible secondary trapeziectomy
    • AddedPatient rated wrist and hand evaluation (PRWHE) - pain subscaleTime frame: At baseline, 3 months, 6 months, and 1, 2, 5 years after randomization, 6 months after possible secondary trapeziectomy
    • AddedPatient rated wrist and hand evaluation (PRWHE) - function subscaleTime frame: At baseline, 3 months, 6 months, and 1, 2, 5 years after randomization, 6 months after possible secondary trapeziectomy
    • AddedEuroQol EQ-5D-5L, Visual Analogue Scale (VAS) (EQ VAS)Time frame: At baseline, 3 and 6 months, and 1, 2, and 5 years after randomization
    • AddedPinch strengthTime frame: At baseline, 6 months after randomization
    • AddedPain medicationTime frame: At baseline, 3 months, 6 months, and 1, 2, 5 years after randomization
    • AddedHarmsTime frame: After intervention (intraoperative), at 3 months, 6 months, and 1, 2, 5 years after randomization and as unprompted participant contacts
    • Addedother outcomeAdherence to post operative rehabilitationTime frame: at 3 months after randomization
    • Addedother outcomeUnblindingTime frame: at 3 months, 6 months, and 1, 2, 5 years after randomization
    • Addedother outcomeCross-overTime frame: at 3 months, 6 months, and 1, 2, 5 years after randomization
    Interventions Arm changed Sham surgery→Placebo surgery
    Sponsor Collaborators added: Hospital Nova, Central Finland·Kuopio University Hospital; collaborators removed: Central Finland Central Hospital·University of Eastern Finland
    Contact Study contact's phone or email changed: j•••@pshp.fi→j•••@pirha.fi. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Helsinki University Central Hospital · Helsinki, FinlandContact none listed→S•••@hus.fi · •••4955
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05127005
Collaborators
Hospital Nova, Central Finland, Kuopio University Hospital, Helsinki University Central Hospital
Responsible party
Jarkko Jokihaara (Associate professor, Tampere University Hospital) — Principal investigator
First posted
Nov 19, 2021
Start date
Jan 20, 2022
Primary completion
Sep 30, 2028 (estimated)
Completion
Mar 31, 2033 (estimated)
Last update
Nov 2, 2026

Study contacts

Jarkko Jokihaara
Contact
jarkko.jokihaara@pirha.fi
+3583311611
Jarkko Jokihaara
study chair · Tampere University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion